.avif)
.avif)
Novo Nordisk Email Format
Pharmaceutical Manufacturing
・
50,001-100,000 employees
・
Bagsværd, Denmark
Novo Nordisk is a Danish pharmaceutical company that develops and manufactures treatments for diabetes, obesity, and other serious chronic diseases, serving patients in over 80 countries worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@novonordisk.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1923
Headquarters
Bagsværd, Denmark
Revenue
$25B-$50B
FUNDING Stage
Public
Website
Key Executives
Maziar Mike Doustdar (President and Chief Executive Officer (CEO)), Karsten Munk Knudsen (Executive Vice President, Chief Financial Officer (CFO)), Emil Kongshoj Larsen (Executive Vice President, International Operations)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Novo Nordisk?
Novo Nordisk uses the firstinitiallast format, so Jane Smith would be jsmith@novonordisk.com.
What are Novo Nordisk's two main business segments?
Novo Nordisk operates through two business segments: Diabetes and Obesity Care, which includes products like Ozempic and Wegovy, and Rare Diseases, which covers rare blood disorders and endocrine conditions.
How many countries does Novo Nordisk's International Operations unit cover?
Novo Nordisk's International Operations unit covers 194 countries and reaches roughly 95% of the world's population, making it the largest operational unit within the company.
Who is the CEO of Novo Nordisk in 2026?
Maziar Mike Doustdar has served as President and CEO of Novo Nordisk since August 2025. He is the first non-Danish person to lead the company since its founding in 1923. You can use Clay to find and verify his current contact details for outreach.
Does Novo Nordisk have an approved oral version of Wegovy for weight loss?
Yes. The FDA approved Novo Nordisk's oral Wegovy pill in late 2025, and it launched commercially in January 2026, making it the first oral GLP-1 therapy approved for weight loss in the United States.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating